Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
April 27th, 2018
8.4K views
This protocol describes a newly established method for virus delivery to the murine prostate. Using either CRISPR/Cas9 technology, gene overexpression, or Cre recombinase delivery, the technique allows orthotopic alteration of gene expression and implements a novel mouse model for prostate cancer.
Overview
This protocol describes a method for virus delivery to the murine prostate, utilizing CRISPR/Cas9 technology for gene editing. This technique enables orthotopic alteration of gene expression and introduces a novel mouse model for studying prostate cancer.
Key Study Components
Area of Science
- Neuroscience
- Gene Editing
- Prostate Cancer Research
Background
- The surgical procedure aims to alter gene expression in the murine prostate.
- Viral delivery of CRISPR/Cas9 guides is employed for prostate cancer induction.
- This method addresses new questions in prostate cancer biology.
- It allows for the analysis and validation of new genes in an in vivo setting.
Purpose of Study
- To enable rapid gene editing of multiple genes.
- To target a subset of prostatic cells, mimicking human scenarios.
- To improve understanding of gene functions in prostate cancer.
Methods Used
- Preparation of anesthetic for surgical procedures.
- Viral delivery techniques for gene editing.
- CRISPR/Cas9 technology for precise gene alteration.
- Use of a novel mouse model for in vivo studies.
Main Results
- Successful alteration of gene expression in murine prostate.
- Demonstrated potential for rapid gene editing.
- Validated the effectiveness of the new mouse model.
- Provided insights into prostate cancer biology.
Conclusions
- The method offers a promising approach for prostate cancer research.
- It enhances the ability to study gene functions in vivo.
- Future studies can build on this technique to explore new therapeutic avenues.
Frequently Asked Questions
What is the main goal of this protocol?
The main goal is to alter gene expression in the murine prostate using viral delivery methods.
What advantages does this method offer?
It allows rapid gene editing of multiple genes by targeting specific prostatic cells.
What challenges might a beginner face?
Beginners may struggle with the organ size and the precision required for successful surgery.
How is the anesthetic prepared for the procedure?
Mix specific volumes of medetomidine, midazolam, butorphanol, and sterile saline.
What technology is primarily used in this study?
CRISPR/Cas9 technology is primarily used for gene editing.
What is the significance of the new mouse model?
It provides a novel platform for studying prostate cancer in vivo.
Executive Industry Relevance
This method enables targeted gene editing in a physiologically relevant prostate cancer model by delivering CRISPR guides via viral vectors to a subset of murine prostate epithelial cells. It addresses a key challenge in oncology R&D: modeling the clonal initiation and progression of tumors that arise from rare cellular events, as seen in human prostate cancer. By reducing reliance on germline models and extensive breeding, the approach accelerates target validation and mechanistic de-risking in discovery pipelines.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses by inducing precise genetic alterations in a small subset of prostate epithelial cells, mimicking human tumor initiation.
- Operational Value: Supports rapid functional validation of candidate genes and pathways without requiring germline crosses or long latency periods.
- Predictive Value: Enhances confidence in target selection by modeling clonal expansion and early transformation events relevant to human disease.
Screening & Assay Development
- Scientific Value: Generates reproducible, in vivo-derived biological systems for assessing the oncogenic potential of genetic perturbations.
- Operational Value: Provides a standardized platform for quantifying phenotypic outcomes such as pAKT activation and GFP reporter expression in defined prostate lobes.
- Scalability Value: Enables parallel testing of multiple guide RNAs or viral constructs in cohorts to support lead identification efforts.
Translational & Preclinical Research
- Scientific Value: Models prostate cancer progression from initiation to invasion through basal membrane, supporting studies of microenvironmental interactions and metastatic potential.
- Operational Value: Allows longitudinal monitoring of tumor development in immunocompetent mice, improving translational fidelity for preclinical efficacy testing.
- Risk Mitigation: Reduces false positives in target validation by restricting genetic alterations to anatomically and biologically relevant cell subsets.
Pipeline & Workflow Integration
The technique fits within the discovery-to-preclinical continuum by enabling in vivo target validation, supporting assay-ready model generation, and informing go/no-go decisions based on phenotypic readouts such as transformation markers and pathway activation.
- Discovery Biology: Facilitates hypothesis-driven gene editing to assess oncogenic drivers and tumor suppressor loss in a spatially controlled manner.
- Assay Readiness: Produces quantifiable outputs including GFP reporter expression and immunohistochemical staining for pAKT, enabling objective comparison across experimental conditions.
- Analytics: Supports statistical analysis of transformation frequency and phenotypic penetrance in targeted cell populations, aiding in target prioritization.
- Translational Research: Models human-relevant tumor evolution from focal initiation to invasive progression, supporting biomarker co-localization studies.
- Enterprise Reuse: Establishes a reusable surgical and viral delivery platform applicable to multiple genes, pathways, and combination studies in prostate cancer research.
Operational & Enterprise Impact
- Scientific Value: Improves predictive confidence in target validation by reducing mechanistic ambiguity through spatially restricted, inducible gene editing.
- Operational Value: Standardizes tumor induction via reproducible surgical injection and viral titration, minimizing inter-animal variability.
- Strategic Value: Enables faster iteration on target hypotheses, reducing time and cost associated with traditional germline model generation.
- Portfolio Impact: Supports risk-adjusted advancement by providing early in vivo evidence of gene function in a clinically relevant anatomical context.
Implementation Considerations
- Requires expertise in microsurgical techniques, anesthesia management, and postoperative care for murine models.
- Dependent on access to biosafety-rated facilities for viral vector handling and sterile surgical instrumentation.
- Necessitates standardization of viral titer, injection volume, and anatomical targeting to ensure reproducible transduction efficiency.
- Requires validation of cell-type specificity and absence of off-target tissue transduction, particularly in urinary tract-adjacent regions.
- Limited by the payload capacity of viral vectors and potential immune responses to viral components or transgene expression.
Biopharma FAQs
Why is targeting a subset of prostate epithelial cells important for target validation?
Targeting a small subset of cells mimics the clonal origin of human prostate cancer, enabling more physiologically relevant modeling of tumor initiation and progression. This approach avoids confounding effects from widespread epithelial alteration and supports accurate assessment of gene-specific oncogenic potential. It improves predictive confidence by aligning with the heterogeneous, focal nature of human tumorigenesis.
How does viral delivery of CRISPR guides enable independent variable isolation in prostate cancer studies?
The method allows precise delivery of specific guide RNAs to defined prostate lobes, enabling researchers to isolate the effect of individual genetic alterations as independent variables. By controlling viral titer and injection site, the technique minimizes variability in transduction efficiency and off-target effects. This supports rigorous hypothesis testing in discovery pipelines where causal links between genotype and phenotype must be established.
What quantitative dependent variable measurements are enabled by this model?
The model enables quantification of transformation through immunohistochemical detection of pAKT activation and GFP reporter expression in transduced cells. These readouts provide objective, measurable indicators of pathway activation and viral transduction efficiency. Co-staining for pAKT and GFP allows identification of double-positive cells, confirming functional gene editing and phenotypic impact.
Why are replication requirements critical for cross-functional collaboration in this model?
Reproducible surgical delivery and consistent viral transduction are essential for generating reliable data across laboratories and project teams. Standardization of anesthesia, surgical technique, and postoperative care ensures that phenotypic outcomes are attributable to genetic alterations rather than procedural variability. This supports data sharing, target comparison, and collaborative decision-making in preclinical programs.
What statistical analysis capabilities are required before implementing this method in a discovery pipeline?
Implementation requires the ability to quantify transduction efficiency, phenotypic penetrance, and co-localization rates across animal cohorts. Statistical comparison of pAKT-positive and GFP-positive cell frequencies enables assessment of transformation significance. Power analysis based on expected effect sizes and variability is necessary to determine appropriate group sizes for target validation studies.
